Compare TMDX & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | PCVX |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 6.0B |
| IPO Year | 2019 | 2020 |
| Metric | TMDX | PCVX |
|---|---|---|
| Price | $136.66 | $46.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $133.00 | $101.67 |
| AVG Volume (30 Days) | 835.5K | ★ 1.5M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.70 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $566,354,000.00 | N/A |
| Revenue This Year | $38.84 | N/A |
| Revenue Next Year | $20.43 | N/A |
| P/E Ratio | $53.83 | ★ N/A |
| Revenue Growth | ★ 41.20 | N/A |
| 52 Week Low | $55.00 | $27.66 |
| 52 Week High | $156.00 | $94.60 |
| Indicator | TMDX | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 51.97 |
| Support Level | $133.50 | $43.78 |
| Resistance Level | $156.00 | $48.11 |
| Average True Range (ATR) | 8.50 | 1.99 |
| MACD | 0.41 | -0.49 |
| Stochastic Oscillator | 55.98 | 42.99 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.